GoodRx Announces $250 Million Share Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
GoodRx Holdings Inc. (GDRX) PT Lowered to $20 at JPMorgan
March 1, 2022 4:58 AM ESTJPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.
The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More
GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook
February 28, 2022 5:31 PM ESTGoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the companys disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.
Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year... More
GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street
February 28, 2022 4:13 PM ESTGoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q4 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $217.53 million.
GUIDANCE:
GoodRx Holdings, Inc. sees Q1 2022 revenue of ~$200 million, versus the... More



